A study to determine efficacy and safety of all-trans retinoic acid (ATRA) combined with low-dose apatinib in patients with recurrent/metastatic adenoid cystic carcinoma of the head and neck
Latest Information Update: 24 Jul 2021
At a glance
- Drugs Rivoceranib (Primary) ; Tretinoin (Primary)
- Indications Adenoid cystic carcinoma; Head and neck cancer
- Focus Therapeutic Use
- 24 Jul 2021 New trial record
- 08 Jun 2021 Results of preliminary analysis (n=16) presented at the 57th Annual Meeting of the American Society of Clinical Oncology